By Paul Goodwin, Analyst and Editor of Cabot China & Emerging Markets Report
From Cabot Wealth Advisory, 5/20/10. Sign up for free Cabot Wealth Advisory e-newsletter
When markets are dealing out losses left and right, as they are now, it's a good idea to pull in your horns and keep lots of cash in your account. But that doesn't mean you can just put your feet up and enjoy a refreshing beverage.
The construction of a Watch List of likely stocks is, itself, a dividend-paying investment.
My candidate for further observation is a small (market cap of $328 million), thinly traded (130,000 shares per day, on average) Chinese biopharmaceutical company called China Biologic Products (CBPO). The stock uplisted to the Nasdaq exchange just last November, and it has been performing well despite a challenging market environment.
The company's lead product is human albumin, a blood protein that accounted for half of 2009 revenues, and various forms of immunoglobulin. Albumin is vital during medical emergencies and immunoglobulin can prevent and treat many diseases.
The company's 2009 sales were up 155% over 2008, and Q1 results showed a 27% gain in earnings on a 28% jump in revenues, with a 27.1% after-tax profit margin. Expansion is coming via both M&A activity and construction of new plasma collection stations.
This is a great stock for your watch list, and when the market turns up again it may provide your portfolio with a real shot in the arm.
Cabot China & Emerging Markets Report: The #1 Financial Newsletter for Five Years
One investment advisory is beating the market with incredible returns over the last five years. Hulbert Financial Digest ranks it #1 for performance during that time—up a huge 128% versus the market’s gain of 1.5%. And there’s more where that came from. Don’t miss out on the next five years of monster growth! Join us today:
Cabot China & Emerging Markets Report
Paul Goodwin Emerging Markets Specialist, Analyst and Editor of Cabot China & Emerging Markets Report
A researcher and writer for over 30 years, Paul Goodwin has been a member of the Cabot investment team and editor of
Cabot China & Emerging Markets Report since 2005. Under Paul’s stewardship, Hulbert Financial Digest rated Cabot China & Emerging Markets Report the number-one-rated newsletter of 2006 with a 78.6% gain for the year, the number-one-rated newsletter of 2007 with a 74.1% return, and the top-performing investment adivsory for five years with a 17.9% annual return.